Hong Kong Regen Medtech Limited

Dr. Kirsty Lee is a medical oncologist trained in Hong Kong and Australia, with clinical expertise in lung, women’s/breast and gastrointestinal cancers. She is an Honorary Associate Professor (Clinical) at The Chinese University of Hong Kong and has served as a regular speaker and advisory board member in lung cancer and molecular diagnostics. Prior to joining Hong Kong Regen Medtech Ltd. as Chief Medical Officer, she worked as a clinical investigator and medical trainer at CUHK and served as Chief Medical Officer at ACT Genomics Ltd.

Ricky Chan is a seasoned biotech finance executive with deep experience scaling life science startups, driving commercialization and leading complex healthcare operations. As Chief Financial Officer of Hong Kong Regen Medtech Limited, he oversees finance, treasury, investor relations and risk management, while supporting the company’s broader business strategy. Under his financial leadership, HKRM has raised over HK$100 million in funding and advanced the financial planning and regulatory setup of its PIC/S GMP stem cell facility at HKSTP. Ricky previously served as CFO of Sanomics Limited, where he supported Pan-Asian market expansion and helped secure more than HK$100 million in private equity and public funding. He began his career at KPMG and is a Practising Certified Public Accountant in Hong Kong.

Dr. Nicodemus Wong is a passionate stem cell scientist and regenerative medicine expert with over a decade of experience driving innovation in cell and gene therapies. He is dedicated to bridging cutting-edge research with clinical translation—transforming breakthrough stem cell technologies into safe, effective, and scalable treatments that improve patients' lives. Dr. Wong holds a BSc (Honours) in Biomedical Sciences from McMaster University, Canada, and a PhD in stem cell biology and regenerative medicine from The University of Hong Kong, with postdoctoral fellowships at HKU and CUHK. He has published 8 peer-reviewed journal articles. As Authorized Person and QC Manager at HKRM, he leads the development of advanced manufacturing processes for Advanced Therapy Products, focusing on process optimization, scalability, quality control, and GMP-compliant production.

Dr. Leung Ho Chuen holds a PhD and a Post Graduate Diploma in Pharmaceutical Quality and Regulation. He is the Production Manager at HKRM, a PIC/S GMP-certified facility specialising in advanced cell therapy manufacturing, and is a Registered Authorized Person (AP). With extensive experience in Hong Kong's biotechnology industry since 2014, his background spans molecular diagnostics, cord blood and tissue banking, and stem cell manufacturing. In his current role, he is responsible for designing and managing the end-to-end manufacturing processes of mesenchymal stem cells (MSCs) within the PIC/S GMP facility, ensuring compliance, quality, and operational excellence.